Clinical Trial: Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539090) titled 'Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)' on April 13.

Brief Summary: The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Healthy Participants

Intervention: DRUG: Vimseltinib

Administered orally

DRUG: Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])

Administered o...